51 reports

  • KEY BUYING CRITERIA FOR GLOBAL AUTOIMMUNE AND INFLAMMATORY IMMUNOMODULATORS MARKET 2015
  • KEY MARKET HIGHLIGHTS

It causes chronic inflammation of any part or the entire gastrointestinal tract.

  • Arthritis
  • Cancer Immunotherapy
  • Therapy
  • AbbVie Inc.
  • Amgen Inc.
  • CANCER VACCINES MARKET, GLOBAL, PIPELINE FOR THERAPEUTIC VACCINES BY INDICATION AND MOLECULAR
  • CANCER VACCINES MARKET, GLOBAL, APPROVED INDICATIONS FOR CERVARIX, 2016

Dietary factors have a substantial influence on the risk of cancers of the gastrointestinal tract.

  • Cancer
  • Cancer Immunotherapy
  • Cell Therapy
  • Therapy
  • Vaccine

Focuses on areas such as cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; neuroscience; and gastrointestinal tract.

  • Cancer Immunotherapy
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.

Advances in the treatment of gastrointestinal stromal tumours.

  • Cancer Immunotherapy
  • World
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Pfizer Inc.

Aduro announced the promising initial results from the first Phase ## trial of this combination therapy at the American Society of Clinical Oncology (ASCO) 2014 Gastrointestinal Cancers Symposium.

  • Cancer Immunotherapy
  • World
  • Altor BioScience Corporation
  • GlobeImmune, Inc.
  • Merck & Co., Inc.

gastrointestinal, anti-infectious (antibacterial, antiviral), cardiovascular, anti-cancer, immunomodulant, reproductive, neurological, urological, dermatological and pediatric agents.

  • Cancer Immunotherapy
  • Renal Cancer
  • Therapy
  • China
  • Bayer Schering Pharmaceutical Co., Ltd
  • Pipeline Landscape Assessment

Other symptoms include retrosternal pain, weight loss, hematemesis (vomiting blood) and melena (black feces associated with gastrointestinal hemorrhage).

  • Cancer Immunotherapy
  • World
  • Market Size
  • Celgene Corporation
  • Merck & Co., Inc.

Cervarix users report fatigue, headache, myalgia, gastrointestinal problems, and arthralgia after vaccination.

  • Cancer Immunotherapy
  • Dendreon Corporation
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • PROVENGE group

GASTROINTESTINAL; CARDIOVASCULAR AND METABOLIC DISEASES; ONCOLOGY AND RESPIRATORY INFLAMMATION AND AUTOIMMUNITY.

  • Cancer Immunotherapy
  • United States
  • Agenus Inc.
  • Incyte Corporation
  • Merck & Co., Inc.

PD-## BLOCKADE IN MISMATCH REPAIR DEFICIENT NON-COLORECTAL GASTROINTESTINAL CANCERS.

  • Cancer
  • Cancer Immunotherapy
  • Lung Cancer
  • Pathology
  • Therapy
  • LIST OF ABBREVIATIONS

gastrointestinal disorders, fungal infection, HIV/ AIDS, allergies, and cancer.

  • Cancer
  • Cancer Immunotherapy
  • Hospital
  • Therapy
  • American Cancer Society, Inc.
  • DORMANT PRODUCTS, H2 2017 (CONTD..1), H2 2017
  • DORMANT PROJECTS (CONTD..1), H2 2016

Waxman, M. D., development lead, Gastrointestinal Cancers, Bristol-Myers Squibb.

  • Cancer
  • Cancer Immunotherapy
  • Monoclonal Antibody
  • Oncology
  • Therapy

Results from the Phase I study were presented at the 2017 Gastrointestinal Cancers Symposium. ## G/ GEJ pts have been enrolled in the study.

  • Cancer
  • Cancer Immunotherapy
  • Chemotherapy
  • Lung Cancer
  • Therapy
  • presented, at the 2016 European Society for Medical Oncology (ESMO) Congress during an oral...
  • Research and Development Brief

Results from the Phase I/ II study were presented at the 2017 Gastrointestinal Cancers Symposium.

  • Cancer Immunotherapy
  • Chemotherapy
  • Lung Cancer
  • Therapy
  • Merck & Co., Inc.
  • brentuximab + bendamustine for participants with a suboptimal response. The trial was registered...
  • Phase I - Trial Details

Results from the Phase I/ II study were presented at the 2017 Gastrointestinal Cancers Symposium.

  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • United States
  • Bristol-Myers Squibb Company
  • brentuximab + bendamustine for participants with a suboptimal response. The trial was registered...
  • Phase I - Trial Details

Results from the Phase I/ II study were presented at the 2017 Gastrointestinal Cancers Symposium.

  • Cancer Immunotherapy
  • Therapy
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company

Abstract Number: TPS## Location: Hall A Poster Board: ##b Poster Session: Gastrointestinal (Noncolorectal) Cancer Presenter: Ghassan K.

  • Biotherapeutic
  • Cancer
  • Cancer Immunotherapy
  • United States
  • BioTherapeutics Inc.
  • JUN 05, 2016: NIVOLUMAB SHOWS PROMISE IN FIRST-EVER TRIAL FOR PATIENTS WITH REFRACTORY, METASTATIC...
  • presented, at the 2016 European Society for Medical Oncology (ESMO) Congress during an oral...

Results from the Phase I/ II study were presented at the 2017 Gastrointestinal Cancers Symposium.

  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • United States
  • Product Initiative
  • NIVOLUMAB - DRUG PROFILE

Results from the Phase I/ II study were presented at the 2017 Gastrointestinal Cancers Symposium.

  • Cancer Immunotherapy
  • Therapy
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company

The only dose-limiting toxicities (DLTs) were gastrointestinal in nature.

  • Cancer
  • Cancer Immunotherapy
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • SUBOPTIMAL RESPONSE. THE TRIAL WAS REGISTERED WITH THE U.S. NATIONAL INSTITUTES OF HEALTH.

The Phase III soft tissue sarcoma trial population excluded patients with adipocytic soft tissue sarcoma (liposarcoma) or gastrointestinal stromal tumor.

  • Cancer
  • Cancer Immunotherapy
  • Hospital
  • Lung Cancer
  • Therapy
  • registered with U.S.
  • IPILIMUMAB + NIVOLUMAB - DRUG PROFILE

The data were presented at the 2017 Gastrointestinal Cancers Symposium in San Francisco, California. ##-Dec-2016 Ono Pharmaceutical Co.

  • Cancer
  • Cancer Immunotherapy
  • Pharmaceutical
  • Therapy
  • Bristol-Myers Squibb Company
  • Mechanism Of Action
  • Phase I - Trial Details

It is in Phase II stage of development for gastrointestinal stromal tumors (GIST).

  • Cancer
  • Cancer Immunotherapy
  • Lung Cancer
  • Therapy
  • Merck & Co., Inc.
  • Licensing and Collaboration
  • Research and Development Brief

Results from the Phase I/ II study were presented at the 2017 Gastrointestinal Cancers Symposium.

  • Cancer
  • Cancer Immunotherapy
  • Lung Cancer
  • Pharmaceutical
  • Therapy
  • JUN 05, 2016: NIVOLUMAB SHOWS PROMISE IN FIRST-EVER TRIAL FOR PATIENTS WITH REFRACTORY, METASTATIC...
  • NIVOLUMAB - DRUG PROFILE

Results from the Phase I/ II study were presented at the 2017 Gastrointestinal Cancers Symposium.

  • Cancer
  • Cancer Immunotherapy
  • Therapy
  • United States
  • Product Initiative

IB-##C## - DRUG PROFILE MONOCLONAL ANTIBODY TO INHIBIT IL-## AND IL-## FOR ONCOLOGY, CENTRAL NERVOUS SYSTEM AND GASTROINTESTINAL DISORDERS - DRUG PROFILE PROSTATAC - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Prostatac On

  • Cancer Immunotherapy
  • Hospital
  • United States
  • World
  • Product Initiative

It focuses on the research and development, manufacture, and sale of medicines for the treatment of cancer, cardiovascular diseases, central nervous system disorders, ophthalmic diseases, gastrointestinal and respiratory diseases, infectious diseases, dermatological conditions and allergies

  • Cancer
  • Cancer Immunotherapy
  • Vaccine
  • United States
  • Product Initiative
  • Comparison of First-in-Class to Established Products in the Cancer Immunotherapies Pipeline...
  • Summary of Incidence, Mortality, Mortality Rates and Cancer Immunotherapies Pipeline Activity...

According to the previous data these cancers are leukemias, and lung, colorectal, pancreatic, gastrointestinal and liver cancer.

  • Cancer Immunotherapy
  • Monoclonal Antibody
  • Oncology
  • Therapy
  • World

This work was supported by a Rutgers Cancer Institute of New Jersey Gastrointestinal Oncology Pilot Grant to Drs.

  • Cancer Immunotherapy
  • Vaccine
  • United States
  • Product Initiative
  • Vaxil
  • NIVOLUMAB - DRUG PROFILE

National Institutes of Health. ##-Oct-2016 Olivia Newton-John Cancer Research Institute in collaboration with Bristol-Myers Squibb registered a Phase II open label trial to evaluate the safety and efficacy of ipilimumab and nivolumab in combination for the treatment of rare

  • Cancer
  • Cancer Immunotherapy
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company